Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2017 Sep 1.

Published in final edited form as: Nature. 2017 Mar 1;543(7644):270–274. doi: 10.1038/nature21688

Extended Data Figure 4 — (a) CRISPR-Cas9 knockout of endogenous ENL in MV4;11 (Cas9+, ENL-FKBP12^F36V-HA+) cells. ENL/HA immunoblot in MV4;11 (Cas9+, ENL-FKBP12^F36V-HA+) (P, parental) and MV4;11 (Cas9+, ENL-FKBP12^F36V-HA+, ENL^−/−) cells.

(b) CRISPR-Cas9 knockout of endogenous ENL in MV4;11 (Cas9+, FKBP12^F36V-HA-ENL+) cells.

(c) DMSO-normalized cellular viability of MV4;11 (Cas9+, ENL-FKBP12^F36V-HA+, ENL^−/−) cells after 72-hour treatment with dTAG-13 approximated by ATP-lite assay (means ± s.d., n = 4).

(d) DMSO-normalized cellular viability of MV4;11 (Cas9+, FKBP12^F36V-HA-ENL+, ENL^−/−) cells after 72-hour treatment with dTAG-7 or dTAG-13 approximated by ATP-lite assay (means ± s.d., n = 4).

(e) Growth over time of MV4;11 (Cas9+, ENL-FKBP12^F36V-HA+, ENL^−/−) cells treated with DMSO or dTAG-13 (500 nM). Total number of viable cells as approximated by trypan blue exclusion is plotted over time (means ± s.d., n = 3).

(f–g) As in (e), but with cell line indicated at top.

(h) As in (d), but with wild-type MV4;11 cells.

(i) Representative plots of BrdU incorporation used for cell cycle analysis shown in Fig. 2f.